Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

17.12USD
21 Feb 2017
Change (% chg)

$-0.02 (-0.12%)
Prev Close
$17.14
Open
$17.11
Day's High
$17.30
Day's Low
$16.99
Volume
274,817
Avg. Vol
376,069
52-wk High
$17.30
52-wk Low
$8.18

IRWD.OQ

Chart for IRWD.OQ

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company's products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $2,506.27
Shares Outstanding(Mil.): 146.22
Dividend: --
Yield (%): --

Financials

  IRWD.OQ Industry Sector
P/E (TTM): -- 47.00 29.32
EPS (TTM): -0.57 -- --
ROI: -13.91 -4.07 13.03
ROE: -102.85 4.71 14.17

BRIEF-Ironwood pharmaceuticals qtrly loss per share $0.09

* Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million.

Feb 21 2017

BRIEF-Ironwood Pharmaceuticals and Allergan entered into amendment to license agreement, dated April 30, 2009

* Ironwood Pharmaceuticals Inc - Co and Allergan Pharmaceuticals International Ltd. entered into amendment to license agreement, dated April 30, 2009

Feb 01 2017

BRIEF-Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan

* Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan

Jan 29 2017

BRIEF-Ironwood Pharma Q3 adj shr loss $0.18 vs est $-0.23

* Ironwood pharmaceuticals - now expects to use less than $50 million in cash for operations in 2016, down from previous guidance of less than $70 million

Nov 03 2016

More From Around the Web

Earnings vs. Estimates